Literature DB >> 11445273

Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease.

E Savaskan1, G Olivieri, L Brydon, R Jockers, K Kräuchi, A Wirz-Justice, F Müller-Spahn.   

Abstract

The pineal hormone melatonin has two major functions: as a transducer of the circadian day-night signal across the seasons, and as a vasoactive substance regulating cerebral circulation. The vasoconstrictive effects of melatonin have been postulated to be mediated by the melatonin 1a-receptor (MT1). The objective of this study was to provide the first immunohistochemical evidence for the localization of vascular MT1 in human control hippocampus compared to Alzheimer's disease (AD) patients, since regional blood flow impairments contribute to the neurodegenerative course of the disease. Both superficial and intrahippocampal arteries revealed MT1 immunoreactivity in adventitia in controls, which was distinctly increased in AD patients. The increased MT1 in AD may indicate a regulatory response to impaired melatonin levels in those patients, contributing to the regulation of cerebral circulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445273     DOI: 10.1016/s0304-3940(01)01967-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

1.  Melatonin MT-1-receptor immunoreactivity in the human eye.

Authors:  P Meyer; M Pache; K U Loeffler; L Brydon; R Jockers; J Flammer; A Wirz-Justice; E Savaskan
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

2.  The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization.

Authors:  Angélique Levoye; Julie Dam; Mohammed A Ayoub; Jean-Luc Guillaume; Cyril Couturier; Philippe Delagrange; Ralf Jockers
Journal:  EMBO J       Date:  2006-06-15       Impact factor: 11.598

Review 3.  Melatonin receptors: molecular pharmacology and signalling in the context of system bias.

Authors:  Erika Cecon; Atsuro Oishi; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

Review 4.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 5.  Functional MT1 and MT2 melatonin receptors in mammals.

Authors:  Margarita L Dubocovich; Magdalena Markowska
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 6.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

7.  Melatonin improves memory acquisition under stress independent of stress hormone release.

Authors:  Ulrike Rimmele; Maria Spillmann; Carmen Bärtschi; Oliver T Wolf; Cora S Weber; Ulrike Ehlert; Petra H Wirtz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

8.  Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander
Journal:  Neurobiol Dis       Date:  2013-03-26       Impact factor: 5.996

Review 9.  Physiological and metabolic functions of melatonin.

Authors:  J Barrenetxe; P Delagrange; J A Martínez
Journal:  J Physiol Biochem       Date:  2004-03       Impact factor: 4.158

Review 10.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.